Jacob B. Schwarz, Ph.D.
Head of Chemistry
Jake has nearly twenty years of medicinal chemistry experience and has held positions of increasing importance in the Parke-Davis, Pfizer, and Genentech organizations.
During this time he contributed to the discovery of several clinical candidates including imagabalin, a calcium channel modulator for generalized anxiety disorder, BIIB-104, an AMPA positive allosteric modulator for cognitive symptoms in schizophrenia, and GDC-0994, an ERK1/2 inhibitor for the treatment of solid tumors. Most recently Jake held the title of Director, Drug Discovery at FLX Bio and led a team that discovered FLX193, a best in class CCR4 antagonist for allergic diseases.
He is a member of the Executive Committee of the American Chemical Society's Division of Medicinal Chemistry, and currently holds the position of Program Chair. Jake received a Ph.D. from Colorado State University under the guidance of A. I. Meyers, followed by an NIH postdoctoral fellowship in the laboratories of Samuel Danishefsky at Memorial Sloan-Kettering Cancer Center.